The global ovarian cancer diagnostics market size is projected to expand at a substantial CAGR during the forecast period, 2021 – 2028. The growth of the market is attributed to the rising prevalence of ovarian cancer and increasing emphasis on wide adoption of its diagnosis & treatment.
Ovarian cancer is a specific type of cancer, which is only related to cancer formation in female organ. Among different types of ovarian cancer, the epithelial ovarian cancer is the most common one and this is one of the most leading causes of increasing mortality rate of women around the world. According to a public health data, it is the fifth leading cause of cancer death in women worldwide and the tenth common cause of cancer death among women in the US.
In general, the detection of ovarian cancer in the early stage remains difficult until it starts affecting other organs around the pelvis and stomach. Since most patients are diagnosed at an advanced stage, the disease's prognosis is still low. As a result, there is an urgent need for further research into disease biology in order to establish successful treatment options with the aim of overcoming resistance while minimizing toxicity. Furthermore, biomarker discovery is considered to be a key means for aiding in the effective identification of patients that need ongoing treatment. Bloating, irregular menstruation, menstrual bleeding, indigestion, and fatigue are some of the signs of the disorder. As per several scientific studies, a deeper understanding of the fundamental molecular processes is urgently needed in order to identify genetic elements or biochemical pathways that could be targeted for diagnosis and treatment.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing prevalence of ovarian cancer and rising awareness about the availability of advanced diagnostic devices are key factors driving the market growth.
- Rising healthcare expenditure and increasing technological advancements for effective diagnosis are expected to propel the market expansion during the forecast period.
- Several favorable governments’ programs and their increasing support for ovarian cancer research are expected to boost the market growth in the coming years.
- Lack of information about the exact origin and causative factors of the illness and late diagnosis of the disease are major challenges that can hamper the market growth.
- Ongoing R&D activities to expand the treatment and diagnostic technique are providing several key opportunities for the overall market expansion.
Scope of the Report
The report on the global ovarian cancer diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Ovarian Cancer Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2020
|
|
Historic Data
|
2018–2019
|
|
Forecast Period
|
2021–2028
|
|
Segmentation
|
Types (Imaging [Ultrasound, CT Scan, MRI Scan, PET Scan, and Others], Blood Tests [CA125, HER2, BRCA, CEA, ER & PR, KRAS Mutation, and Others], Biopsy, and Others), Cancer Types (Epithelial Tumor, Stromal Cell Tumor, Germ Cell Tumor, and Others), End-users (Hospital Laboratories, Cancer Diagnostic Centers, Research Institutes, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Johnson & Johnson Services, Inc.; AstraZeneca plc; Siemens Healthcare GmbH; Quest Diagnostics Incorporated.; Thermo Fisher Scientific; Bio-Rad Technologies Inc.; and Abbott.
|
Ovarian Cancer Diagnostics Market Segment Insights
Imaging segment is expected to account for a large market share
Based on types, the global ovarian cancer diagnostics market is divided into imaging, blood test, biopsy, and others. The imaging segment is further classified as ultrasound, CT scan, MRI scan, PET scan, and others while the blood tests segment as CA125, HER2, BRCA, CEA, ER & PR, KRAS mutation, and others. The imaging segment is expected to account for a key share of the market owing to wide adoption of imaging method due to the growing importance of early detection and cancer staging. The preliminary imaging method also known as trans-vaginal ultrasound is widely adopted for detecting and measuring the size of a tumor internally. While CT scans are recommended for cancer staging, they are only appropriate for small tumors. To diagnose metastasis and the seriousness of the disease, more sophisticated imaging methods such as MRI and PET scans are used.
However, the blood test segment is anticipated to expand at a steady pace during the forecast period. With the rapid technological advances and growing customer awareness, the demand for blood tests is rising steadily over the years. Increased levels of certain biomarkers, which function as tumor markers and help in diagnosis, may occur as a result of ovarian cancer. The most common blood test for this disorder, for example, is CA-125. Greater market penetration for HER2, BRCA, and KRAS mutation tests have resulted to growing focus on genetic therapy and tests.
Epithelial Tumor segment is projected to constitute a major share
On the basis of cancer types, the market is segmented into epithelial tumor, stromal cell tumor, germ cell tumor, and others. The epithelial tumor segment is projected to constitute a major share of the market in the coming years and held more than 85% share of all ovarian malignancies in 2020. Serous, mucinous, endometrioid, and clear cell epithelial tumors are all types of epithelial tumors. The majority of epithelial cell carcinoma patients who are diagnosed after the tumor has spread to the peritoneal cavity. Around 70-80% of patients are diagnosed at an advanced stage, which leads to limiting care options and survival rates dramatically. Meanwhile, the germ cell and stromal cell tumors together is anticipated to account for a considerable share of the market in the coming years. Stromal tumors arise in the tissues that produce hormones including estrogen, progesterone, and testosterone. Germ cell tumors are mostly common in women who are between the aged of 20 to 30 years old, despite their rarity.
Research institute segment is expected to grow at rapid pace
Based on end-users, the global ovarian cancer diagnostics market is divided into hospital laboratories, cancer diagnostic centers, research institutes, and others. The hospital laboratories segment is expected to hold a large market share owing to increasing patient inflow for cancer diagnosis in hospitals. Moreover, rapid expansion of laboratory tests in hospitals present a key driving factor for the segment growth. However, the research institute segment is anticipated to expand at a rapid pace during the forecast period due to increasing investments towards healthcare research in collaboration with research institutes especially in developed regions. The Fred Hutchinson Cancer Research Center, for example, is focusing towards the discovery of biomarkers and ovarian cancer screening.
Asia Pacific market is anticipated to expand at a high CAGR
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Due to good commercial performances of gynecologic diagnostics especially in the US, North America accounted for more than 40.5 percent of the overall market share in 2020. Other factors contributing to the regional market growth include favorable government policies, a rise in healthcare spending, and the presence of key manufacturers. On the other hand, the market in Asia Pacific is projected to expand at a high CAGR during the forecast period due to factors such as economic growth, improved healthcare infrastructure, increased disposable income, and increased market awareness. Emerging markets such as China, India, and South Korea are expected to experience rapid growth in the ovarian cancer diagnostics market in the coming years.
Segments
Segments Covered in the Report
The global ovarian cancer diagnostics market has been segmented on the basis of
Types
- Imaging
- Ultrasound
- CT Scan
- MRI Scan
- PET Scan
- Others
- Blood Tests
- CA125
- HER2
- BRCA
- CEA
- ER & PR
- KRAS Mutation
- Others
- Biopsy
- Others
Cancer Types
- Epithelial Tumor
- Stromal Cell Tumor
- Germ Cell Tumor
- Others
End-users
- Hospital Laboratories
- Cancer Diagnostic Centers
- Research Institutes
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc.
- Johnson & Johnson Services, Inc.
- AstraZeneca plc
- Siemens Healthcare GmbH
- Quest Diagnostics Incorporated.
- Thermo Fisher Scientific
- Bio-Rad Technologies Inc.
- Abbott
Competitive Landscape
Some of the key players operating in the market are F. Hoffmann-La Roche Ltd.; GlaxoSmithKline plc; Johnson & Johnson Services, Inc.; AstraZeneca plc; Siemens Healthcare GmbH; Quest Diagnostics Incorporated.; Thermo Fisher Scientific; Bio-Rad Technologies Inc.; and Abbott. This market is increasingly competitive as major players concentrate more on strategic strategies including product launches, mergers and acquisitions, licencing alliances, and co-development deals. Foundation Medicine, for example, announced in June 2019 that its Foundation One CDx, a detailed genomic profiling test, had obtained the US Food and Drug Administration (FDA) approval for use as a companion diagnostic for LYNPARZA (Olaparib) in first-line maintenance therapy for BRCA-mutated metastatic ovarian cancer. BRCA1/2 mutations both germline and somatic, can be detected using this test.
Request For Customization
Enquiry Before Buying
Speak With Analyst
